drugset / Trial / NCT02157935

Comparing the Efficacy of Symbicort® pMDI and Formoterol Turbuhaler in Reducing Exacerbations in Patients With Cronic Obstructive Pulmonary Disease

NCT02157935

Phase 3 Completed 2026 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

Comparing the efficacy of Symbicort® pMDI and Formoterol Turbuhaler in reducing exacerbations in patients with Chronic Obstructive Pulmonary Disease (COPD).

Timeline

Start
2014-06-27
Primary completion
2016-02-08
Completion
2016-02-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Budesonide Small molecule 160 ug Inhaled
Comparator Formoterol Other / unclassified 4.5 ug Inhaled